EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic Countries

Mikkel Z Ankarfeldt iD, Aleksander Søltoft-Jensen, Claudia A Salinas, Angela Lupattelli iD, Eero Pukkala, Kristian Bolin, Sarah Smith, Kristin Joy Meyers, Janne Petersen, Espen Jimenez-Solem

Pharmacoepidemiology and Drug Safety · 2024

DOI: 10.1002/pds.70010 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von Mikkel Z Ankarfeldt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Copenhagen Phase IV Unit (Phase4CPH), Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Frede…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Purines, Sulfonamides, Azetidines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Baricitinib received European Medicines Agency (EMA) approval for the treatment of moderate‐to‐severe active rheumatoid arthritis (RA) in 2017. Due to risks including serious infections, increased blood lipid parameters, and missing information regarding safety in pregnancy, additional risk minimization measures (aRMM) including healthcare professional educational material and a patient alert card were implemented to inform on the risks and actions to minimize risk such as the need to screen for tuberculosis and active viral hepatitis before starting baricitinib, monitoring of blood lipids and against use during pregnancy. The aim of the study is to report occurrences of infections, lipid level monitoring and pregnancies, in real world data, to gain insights into whether baricitinib is used in accordance with the aRMM.

Methods

A descriptive observational cohort study, utilizing routinely collected data from the Swedish, Norwegian, Finnish, and Danish national registries, was carried out. RA patients initiating baricitinib treatment were identified in the periods 2017–19 (Sweden and Finland), 2017–20 (Norway) and 2017–21 (Denmark). Monitored events included pregnancies, cases of tuberculosis, viral hepatitis, and hyperlipidemia, as well as changes in statin prescriptions (including any of initiation, escalation, reduction or change of statin). Hyperlipidemia and statin use served as proxies for lipid level assessment.

Results

Among 3908 patients initiating baricitinib (3373 person‐years exposure), eight pregnancies (1% of 815 women aged 18–50 years) potentially overlapped with treatment. During baricitinib treatment, there was a small number of prevalent cases of tuberculosis (less than three events), and a low prevalence of hepatitis (0.2%), and hyperlipidemia (0.5%), whereas 9.3% had start of or changes in statin prescription, indicating lipid level monitoring.

Conclusion

The study's findings suggest that patients with RA are treated with baricitinib in accordance with the risk minimization recommendations, particularly concerning pregnancy and infection risks. However, the methods used for assessing lipid levels warrant further refinement for more accurate monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidPurinesSulfonamidesAzetidinesPyrazolesAntirheumatic AgentsHumansFemaleMiddle AgedAdultMaleCohort StudiesYoung AdultAdolescentPregnancyScandinavian and Nordic CountriesRegistriesTuberculosisHyperlipidemiasAged

Substanzen

baricitinibPurinesSulfonamidesAzetidinesPyrazolesAntirheumatic Agents

Autor:innen und Institutionen

  • Copenhagen Phase IV Unit (Phase4CPH), Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Frederiksberg, Denmark.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.
  • Health Sciences Unit, Faculty of Social Sciences, Tampere University, Tampere, Finland.
  • Department of Economics. Centre for Health Governance, University of Gothenburg, Göteborg, Sweden.
  • MedEngine, Helsinki, Finland.

ORCID-Profile: Mikkel Z Ankarfeldt, Angela Lupattelli

Förderung

  • Eli Lilly and Company

Zitieren

APA

Ankarfeldt, M. Z., Søltoft-Jensen, A., Salinas, C. A., Lupattelli, A., Pukkala, E., Bolin, K., Smith, S., Meyers, K. J., Petersen, J., & Jimenez-Solem, E. (2024). Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic Countries. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70010

Vancouver

Ankarfeldt MZ, Søltoft-Jensen A, Salinas CA, Lupattelli A, Pukkala E, Bolin K, et al. Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic Countries. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.70010

BibTeX
@article{Ankarfeldt2024,
  author = {Ankarfeldt, Mikkel Z and Søltoft-Jensen, Aleksander and Salinas, Claudia A and Lupattelli, Angela and Pukkala, Eero and Bolin, Kristian and Smith, Sarah and Meyers, Kristin Joy and Petersen, Janne and Jimenez-Solem, Espen},
  title = {Effectiveness of Baricitinib Risk Minimization Activities in Patients With Rheumatoid Arthritis—A Cohort Study in Four Nordic Countries},
  journal = {Pharmacoepidemiology and Drug Safety},
  year = {2024},
  doi = {10.1002/pds.70010}
}
Kostenlos starten →